biocentury week

Pick anything below and it plays in the bar at the foot of the window — and keeps playing while you go on browsing the directory.

1. 1▶Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDABioCentury This Week25:28
   +Listen later
2. 2▶Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOsBioCentury This Week31:43
   +Listen later
3. 3▶Ep. 380 - AZ-BMS rumors, Replimune, psychedelicsBioCentury This Week32:25
   +Listen later
4. 4▶Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecardBioCentury This Week34:09
   +Listen later
5. 5▶Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen dataBioCentury This Week42:07
   +Listen later
6. 6▶Ep. 377 - Trends in life sciences talent with CBRE's Ian AndersonBioCentury This Week29:16
   +Listen later
7. 7▶Ep. 376 - M&A momentum: 3Q public markets previewBioCentury This Week33:01
   +Listen later
8. 8▶Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotechBioCentury This Week33:44
   +Listen later
9. 9▶Ep. 374 - Parkinson's deep dive & FDA trial reformsBioCentury This Week34:14
   +Listen later
10. 10▶Ep. 373 - AbbVie M&A, FDA reversals, a CAR T firstBioCentury This Week30:10
    +Listen later